(RTTNews) - Gold prices were moving lower on Wednesday, extending losses for a third consecutive session as investors assessed the prospect of another Federal Reserve interest-rate increase before the end of the year.
(RTTNews) - Oil prices were little changed on Wednesday, giving up some early gains after data showed Saudi Arabia ramped up production in September despite continued disruption to oil shipments through the Strait of Hormuz.
(RTTNews) - Nxera Pharma Co., Ltd. (4565.T) has entered into an exclusive licensing, supply and commercialization agreement with Synmosa Biopharma Corporation for QUVIVIQ, a treatment for insomnia, across eight Asia-Pacific markets. The deal is intended to broaden access to the t
Key PointsYoung adults with median earnings who save 20% of after-tax income can build a sizable portfolio that pays about $15,000 in annual dividends by retirement.
Key PointsWarren Buffett retired as Berkshire’s CEO on Dec. 31, giving Abel full control over day-to-day operations and the company’s $356 billion investment portfolio.
(RTTNews) - European stocks eked out modest gains on Wednesday as investors cheered strong results from ASML and awaited the release of U.S. CPI data later in the day for additional clues on the Federal Reserve's rate trajectory.
(RTTNews) - NeuroSense Therapeutics Ltd. (NRSN), a late-stage clinical biotechnology company focused on neurodegenerative diseases, announced that its hearing before the Nasdaq Hearings Panel has been scheduled for November 10, 2026, following its appeal of the October 1, 2026, S
Key PointsThiel Macro, an investment company run by Peter Thiel, had 42% of its portfolio invested in Amazon and Vistra Energy as of the second quarter.
(RTTNews) - SciBase Holding AB announced that its skin cancer assessment technology, Nevisense, has received its first positive medical coverage policy from Highmark Blue Cross Blue Shield, marking a significant reimbursement milestone for the company's U.S. business.
(RTTNews) - Rhythm Pharmaceuticals, Inc. (RYTM) announced the commercial launch of Imcivree (setmelanotide) in Japan for acquired hypothalamic obesity, following its inclusion on the country's National Health Insurance (NHI) drug price list.
(RTTNews) - Asian stocks ended mostly lower on Wednesday, even as pressure on tech stocks eased and dovish Fed remarks spurred expectations that the U.S. Federal Reserve may not need to raise interest rates aggressively next year.